NEPWA
MACK

New England Private Wealth Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

New England Private Wealth Advisors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,125
Closed -$105K – 128
2016
Q3 		$105K Hold
2,125
– – 0.04% 119
2016
Q2 		$90K Hold
2,125
– – 0.03% 116
2016
Q1 		$139K Buy
2,125
+101
+5% +$5.27K 0.06% 115
2015
Q4 		$126K Buy
+2,024
New +$142K 0.05% 119

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

New England Private Wealth Advisors's MACK Position: Q4 2016 in Review

New England Private Wealth Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2016, closing a stake of 2,125 shares — an estimated $105K sold.

New England Private Wealth Advisors first reported a position in MACK in Q4 2015 and held it in 4 quarters. The position peaked at $139K in Q1 2016. 136 funds tracked by Wall St. Rank hold MACK as of Q4 2016.

  • New England Private Wealth Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • New England Private Wealth Advisors sold 2,125 Merrimack Pharmaceuticals, Inc. shares in Q4 2016, an estimated $105K.
  • New England Private Wealth Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2015 and held it in 4 quarters.
  • New England Private Wealth Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $139K in Q1 2016.
  • 136 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2016.

Based on New England Private Wealth Advisors's 13F filing for Q4 2016, filed 9 Feb 2017.